Recommended treatment by physicians in elderly patients with lung cancer
Elderly patients, patients with lung cancer, can use immunotherapy, after a study by Italian researchers has shown that it is safe and effective.
The new study, led by Dr. Giulia Galli from the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, examined the results of immunotherapy treatment for 290 patients with advanced NSCLC.
So far, several clinical trials have demonstrated the efficacy of immunotherapy for NSCLC, but these have typically enrolled younger patients.
Patients were treated between 2013 and 2019, and 180 of them were under the age of 70, 94 were between the ages of 70 and 79, and 16 patients were over 80 years old.
Immunotherapy was generally well tolerated, with 27.6% of patients developing grade 2 or higher toxicity, the results of the study, presented recently in Lung Cancer, quoted by Reuters, show.
The response rate to immunotherapy was similar in all three age groups: 21.5% in those under 70 years of age, 22.3% in septuagenarians and 18.8% in patients over 80 years of age, according to 360medical .com.
The study shows that immunotherapy should be considered as a treatment option in elderly patients, and not just those who do not undergo chemotherapy, as is often the case, according to the authors of the research.